{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:46:55Z","timestamp":1794440815527,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013062","name":"G\u00e9nome Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013062","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Calcul Qu\u00e9bec"},{"DOI":"10.13039\/501100021202","name":"Alliance de recherche num\u00e9rique du Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"name":"B\u00e9gin-Plouffe chair in blood stem cell chemogenomics"},{"name":"Research chair in leukemia from Industrielle-Alliance"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      There is an unmet clinical need to identify patients with acute myeloid leukemia and intermediate-risk cytogenetics who benefit from allogeneic hematopoietic stem cell transplantation in first remission, especially among those without\n                      <jats:italic>FLT3<\/jats:italic>\n                      -ITD mutation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed transcriptomic data from the Leucegene cohort composed of 316 patients with acute myeloid leukemia and intermediate-risk cytogenetics who have been treated with intensive chemotherapy. We evaluated associations between gene expression and overall survival or relapse-free survival and we analyzed the interaction between gene expression and allogeneic hematopoietic stem cell transplantation to identify biomarkers that predict the benefit of stem cell transplantation in this subgroup of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified high\n                      <jats:italic>IL1R1<\/jats:italic>\n                      expression (\n                      <jats:italic>IL1R1<\/jats:italic>\n                      <jats:sup>high<\/jats:sup>\n                      ) as a prognostic and predictive marker in the Leucegene cohort.\n                      <jats:italic>IL1R1<\/jats:italic>\n                      <jats:sup>high<\/jats:sup>\n                      (\u2265\u20092.0 transcripts per million) was associated with older age, monocytic differentiation, higher frequency of\n                      <jats:italic>FLT3<\/jats:italic>\n                      -ITD and\n                      <jats:italic>RUNX1<\/jats:italic>\n                      mutations and lower frequency of\n                      <jats:italic>IDH1<\/jats:italic>\n                      \/\n                      <jats:italic>2<\/jats:italic>\n                      and bZIP\n                      <jats:italic>CEBPA<\/jats:italic>\n                      mutations. Patients with\n                      <jats:italic>IL1R1<\/jats:italic>\n                      <jats:sup>high<\/jats:sup>\n                      had lower 5-year overall survival (10% vs 38%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), and higher 5-year cumulative incidence of relapse (76% vs 59%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) than those with low\n                      <jats:italic>IL1R1<\/jats:italic>\n                      expression.\n                      <jats:italic>IL1R1<\/jats:italic>\n                      <jats:sup>high<\/jats:sup>\n                      was independently associated with overall survival in multivariable analyses including age, white blood cell count at diagnosis and\n                      <jats:italic>NPM1<\/jats:italic>\n                      ,\n                      <jats:italic>FLT3<\/jats:italic>\n                      -ITD, bZIP\n                      <jats:italic>CEBPA<\/jats:italic>\n                      ,\n                      <jats:italic>RUNX1<\/jats:italic>\n                      ,\n                      <jats:italic>ASXL1<\/jats:italic>\n                      and\n                      <jats:italic>DNMT3A<\/jats:italic>\n                      mutations (HR 1.78,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Importantly, in landmark analysis, hematopoietic stem cell transplantation in first remission significantly improved 5-year overall survival in patients with\n                      <jats:italic>IL1R1<\/jats:italic>\n                      <jats:sup>high<\/jats:sup>\n                      (67% vs 27%, HR 0.33,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), but not in patients with\n                      <jats:italic>IL1R1<\/jats:italic>\n                      <jats:sup>low<\/jats:sup>\n                      (62% vs 54%, HR 0.72,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.31), especially among those without\n                      <jats:italic>FLT3<\/jats:italic>\n                      -ITD mutation (48% vs 50%, HR 0.93,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.85). In patients who proceeded to allogeneic hematopoietic stem cell transplantation, the 5-year overall survival was 60% in patients with\n                      <jats:italic>IL1R1<\/jats:italic>\n                      <jats:sup>high<\/jats:sup>\n                      compared to 56% in patients with\n                      <jats:italic>IL1R1<\/jats:italic>\n                      <jats:sup>low<\/jats:sup>\n                      confirming that the worse prognosis associated with high expression of\n                      <jats:italic>IL1R1<\/jats:italic>\n                      was abrogated by stem cell transplantation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:italic>IL1R1<\/jats:italic>\n                      expression is a candidate marker to identify patients with intermediate-risk cytogenetics acute myeloid leukemia at high risk of relapse who benefit from allogeneic hematopoietic stem cell transplantation in first remission.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40364-025-00827-6","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T08:55:21Z","timestamp":1761209721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort"],"prefix":"10.1186","volume":"13","author":[{"given":"Guillaume","family":"Richard-Carpentier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"B\u00e9liveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Lacoste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banafsheh","family":"Khakipoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Lisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vladovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Marquis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Spinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gendron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Lemieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent-Philippe","family":"Lavall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Sauvageau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e","family":"H\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"11","key":"827_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic: clinical: and genomic data. Blood. 2022;140(11):1200\u201328.","journal-title":"Blood"},{"issue":"7","key":"827_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"2","key":"827_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2): 41.","journal-title":"Blood Cancer J"},{"issue":"12","key":"827_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"3","key":"827_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354\u201365.","journal-title":"Blood"},{"issue":"23","key":"827_CR6","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"10","key":"827_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","volume":"9","author":"JJ Cornelissen","year":"2012","unstructured":"Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhauser M, Juliusson G, et al. The European LeukemiaNet AML working party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"827_CR8","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/cncr.20945","volume":"103","author":"M Yanada","year":"2005","unstructured":"Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer. 2005;103(8):1652\u20138.","journal-title":"Cancer"},{"issue":"22","key":"827_CR9","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349\u201361.","journal-title":"JAMA"},{"issue":"4","key":"827_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1200\/JCO.2013.50.5768","volume":"32","author":"M Stelljes","year":"2014","unstructured":"Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heinecke A, et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol. 2014;32(4):288\u201396.","journal-title":"J Clin Oncol"},{"issue":"11","key":"827_CR11","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1093\/annonc\/mdx500","volume":"28","author":"K Heidrich","year":"2017","unstructured":"Heidrich K, Thiede C, Schafer-Eckart K, Schmitz N, Aulitzky WE, Kramer A, et al. Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD: NPM1- or biallelic CEBPA mutations. Ann Oncol. 2017;28(11):2793\u20138.","journal-title":"Ann Oncol"},{"issue":"4","key":"827_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.2009.22.9088","volume":"28","author":"AK Burnett","year":"2010","unstructured":"Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):586\u201395.","journal-title":"J Clin Oncol"},{"issue":"1","key":"827_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62\u201370.","journal-title":"Blood"},{"issue":"9","key":"827_CR14","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2006-06-025627","volume":"109","author":"JJ Cornelissen","year":"2007","unstructured":"Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658\u201366.","journal-title":"Blood"},{"issue":"4","key":"827_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamaoncol.2022.7605","volume":"9","author":"M Bornhauser","year":"2023","unstructured":"Bornhauser M, Schliemann C, Schetelig J, Rollig C, Kramer M, Glass B, et al. Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with intermediate-risk acute myeloid leukemia: a randomized clinical trial. JAMA Oncol. 2023;9(4):519\u201326.","journal-title":"JAMA Oncol"},{"issue":"7","key":"827_CR16","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.bbmt.2016.03.027","volume":"22","author":"B Oran","year":"2016","unstructured":"Oran B, Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, et al. Allogeneic transplantation in first remission improves outcomes irrespective of FLT3-ITD allelic ratio in FLT3-ITD-positive acute myelogenous leukemia. Biol Blood Marrow Transplant. 2016;22(7):1218\u201326.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"827_CR17","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","volume":"124","author":"RF Schlenk","year":"2014","unstructured":"Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124(23):3441\u20139.","journal-title":"Blood"},{"issue":"2","key":"827_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3324\/haematol.2017.178251","volume":"103","author":"X Poire","year":"2018","unstructured":"Poire X, Labopin M, Polge E, Passweg J, Craddock C, Blaise D, et al. Allogeneic stem cell transplantation benefits for patients >\/= 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2018;103(2):256\u201365.","journal-title":"Haematologica"},{"issue":"18","key":"827_CR19","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","volume":"358","author":"RF Schlenk","year":"2008","unstructured":"Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909\u201318.","journal-title":"N Engl J Med"},{"issue":"5","key":"827_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.2013.54.4973","volume":"33","author":"C Rollig","year":"2015","unstructured":"Rollig C, Bornhauser M, Kramer M, Thiede C, Ho AD, Kramer A, et al. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. J Clin Oncol. 2015;33(5):403\u201310.","journal-title":"J Clin Oncol"},{"issue":"1","key":"827_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","volume":"19","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, et al. NCCN guidelines insights: acute myeloid leukemia: version 2.2021. J Natl Compr Canc Netw. 2021;19(1):16\u201327.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"827_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085150","volume":"9","author":"I Zwiener","year":"2014","unstructured":"Zwiener I, Frisch B, Binder H. Transforming RNA-seq data to improve the performance of prognostic gene signatures. PLoS One. 2014;9(1): e85150.","journal-title":"PLoS One"},{"issue":"1","key":"827_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1182\/blood-2014-07-591529","volume":"125","author":"VP Lavallee","year":"2015","unstructured":"Lavallee VP, Gendron P, Lemieux S, D\u2019Angelo G, Hebert J, Sauvageau G. EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. Blood. 2015;125(1):140\u20133.","journal-title":"Blood"},{"key":"827_CR24","doi-asserted-by":"crossref","unstructured":"Kleinbaum DG, Klein M. Survival analysis. A self-learning text: third edition. Springer New York: NY. 2011:700.","DOI":"10.1007\/978-1-4419-6646-9"},{"issue":"1","key":"827_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14\u201320.","journal-title":"Immunity"},{"key":"827_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01512","volume":"9","author":"SD Jayasingam","year":"2019","unstructured":"Jayasingam SD, Citartan M, Thang TH, Mat Zin AA, Ang KC, Ch\u2019ng ES. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front Oncol. 2019;9: 1512.","journal-title":"Front Oncol"},{"issue":"6","key":"827_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114260","volume":"43","author":"ME Bordeleau","year":"2024","unstructured":"Bordeleau ME, Audemard E, Metois A, Theret L, Lisi V, Farah A, et al. Immunotherapeutic targeting of surfaceome heterogeneity in AML. Cell Rep. 2024;43(6): 114260.","journal-title":"Cell Rep"},{"issue":"1","key":"827_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00769-z","volume":"13","author":"A Metois","year":"2025","unstructured":"Metois A, Bordeleau ME, Theret L, Hajmirza A, Moujaber O, Spinella JF, et al. IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia. Biomark Res. 2025;13(1): 61.","journal-title":"Biomark Res"},{"issue":"5","key":"827_CR29","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/leu.2014.332","volume":"29","author":"JJ Cornelissen","year":"2015","unstructured":"Cornelissen JJ, Versluis J, Passweg JR, van Putten WL, Manz MG, Maertens J, et al. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40\u201360 years. Leukemia. 2015;29(5):1041\u201350.","journal-title":"Leukemia"},{"issue":"2","key":"827_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(11)70326-6","volume":"13","author":"M Pfirrmann","year":"2012","unstructured":"Pfirrmann M, Ehninger G, Thiede C, Bornhauser M, Kramer M, Rollig C, et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol. 2012;13(2):207\u201314.","journal-title":"Lancet Oncol"},{"issue":"9","key":"827_CR31","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367\u201376.","journal-title":"Blood"},{"issue":"1","key":"827_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1182\/bloodadvances.2021004962","volume":"6","author":"S Stratmann","year":"2022","unstructured":"Stratmann S, Yones SA, Garbulowski M, Sun J, Skaftason A, Mayrhofer M, et al. Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression. Blood Adv. 2022;6(1):152\u201364.","journal-title":"Blood Adv"},{"issue":"26","key":"827_CR33","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party. Blood. 2021;138(26):2753\u201367.","journal-title":"Blood"},{"issue":"12","key":"827_CR34","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6(12):1890\u20139.","journal-title":"JAMA Oncol"},{"issue":"19","key":"827_CR35","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood.2023023096","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, et al. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 2024;143(19):1931\u20136.","journal-title":"Blood"},{"issue":"7633","key":"827_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540(7633):433\u20137.","journal-title":"Nature"},{"issue":"3","key":"827_CR37","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41375-019-0604-8","volume":"34","author":"AH Elsayed","year":"2020","unstructured":"Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, et al. A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia. 2020;34(3):735\u201345.","journal-title":"Leukemia"},{"issue":"13","key":"827_CR38","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"A Carey","year":"2017","unstructured":"Carey A, Edwards DKt, Eide CA, Newell L, Traer E, Medeiros BC, et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017;18(13):3204\u201318.","journal-title":"Cell Rep"},{"issue":"24","key":"827_CR39","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1182\/blood-2016-12-754994","volume":"129","author":"CEM de Mooij","year":"2017","unstructured":"de Mooij CEM, Netea MG, van der Velden W, Blijlevens NMA. Targeting the interleukin-1 pathway in patients with hematological disorders. Blood. 2017;129(24):3155\u201364.","journal-title":"Blood"},{"issue":"11","key":"827_CR40","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1002\/art.10578","volume":"46","author":"G Nuki","year":"2002","unstructured":"Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical I. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized: double-blind: placebo-controlled trial. Arthritis Rheum. 2002;46(11):2838\u201346.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"827_CR41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"20","key":"827_CR42","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","volume":"378","author":"F De Benedetti","year":"2018","unstructured":"De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378(20):1908\u201319.","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"827_CR43","doi-asserted-by":"publisher","first-page":"7016","DOI":"10.1200\/JCO.2022.40.16_suppl.7016","volume":"40","author":"G Garcia-Manero","year":"2022","unstructured":"Garcia-Manero G, Winer ES, DeAngelo DJ, Tarantolo SR, Sallman DA, Dugan J, et al. Phase 1\/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed\/refractory (R\/R) acute myeloid leukemia or lyelodysplastic syndrome. J Clin Oncol. 2022;40(16_suppl):7016.","journal-title":"J Clin Oncol"},{"issue":"12","key":"827_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12): 550.","journal-title":"Genome Biol"},{"issue":"43","key":"827_CR45","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00827-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00827-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00827-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:02:49Z","timestamp":1761213769000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00827-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00827-6","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided informed signed consent. This study was in agreement with the declaration of Helsinki and was approved by the Research Ethics Boards of H\u00f4pital Maisonneuve-Rosemont and of Universit\u00e9 de Montr\u00e9al.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}